Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

Horner, Faye; Lip, Peck Lin; Mohammed, Bashar; Fusi-Rubiano, William; Gokhale, Eesha; Mushtaq, Bushra; Chavan, Randhir

doi:10.2147/opth.s305141

Cited by 9 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The follow-up of the participants in the first year of the trial exceeded the associated norms in clinical practice, and patients receiving bevacizumab required more frequent follow-up visits than those receiving aflibercept [17 & ]. This seems to align with the previously argued benefit of aflibercept: that it allows for less frequent dosing than other anti-VEGF medications due to its pharmacologic properties [18][19][20][21].…”

Section: 'Step Therapy' and Variables Affecting Clinical Usesupporting

confidence: 80%

Do published trial results influence physician prescribing patterns? Intravitreal antivascular endothelial growth factor usage by the United States Ophthalmologists before and after Protocol T study

Shah

Markatia

Watane

et al. 2023

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of reviewClinical trial publications may influence physician prescribing patterns. The Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol T study, published in 2015, examined outcomes of intravitreal antivascular endothelial growth factor (VEGF) medications for treatment of diabetic macular oedema (DME). This study investigates if the Protocol T 1-year results were associated with changes in prescribing patterns. Recent findingsAnti-VEGF agents have revolutionized treatment of DME by blocking angiogenesis signalled by VEGF. Three commonly used anti-VEGF agents are on-label aflibercept (Eylea, Regeneron) and ranibizumab (Lucentis, Genentech) and off-label bevacizumab (Avastin, Genentech).

show abstract

Section: 'Step Therapy' and Variables Affecting Clinical Usesupporting

confidence: 80%

Do published trial results influence physician prescribing patterns? Intravitreal antivascular endothelial growth factor usage by the United States Ophthalmologists before and after Protocol T study

Shah

Markatia

Watane

et al. 2023

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

show abstract

“…In hypoxia, the release of VEGF increases exaggeratedly and regulates the adhesion of leukocytes to endothelium. Macrophages also facilitate the migration of choroidal capillaries by eroding already thinned bruch membrane with proteolytic enzymes (13). In AMD, increased VEGF was demonstrated in RPE cells (14).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Photodynamic Therapy-Combined Intravitreal Bevacizumab in Age Related Macular Degeneration

Pangal,

Özkırış

2024

Journal of Anatolian Medical Research

View full text Add to dashboard Cite

Aim: It was aimed to compare treatment results of photodynamic therapy (PDT) and PDT-combined intravitreal bevacizumab injection (PDT+IVB) in patients with age-related macular degeneration (AMD). Material and Methods: 63 eyes of 55 patients with neovascular AMD were included. Group 1 consisted of 40 eyes of 35, group 2 consisted of 23 eyes of 20 patients. Visual acuity (VA), intraocular pressure measurement and fundus examination were performed. Pattern Electroretinography P50 amplitude and edema map values (EMV) were measured with Heidelberg Retina Tomograph (HRTII). Results: VA increased in 14, remained unchanged in 17, decreased in 9 eyes in Group 1 (PDT). The PERG P50 amplitudes were compared with values of pre-treatment, and found increased as 10.6%, 11.98%, and 8.46% and HRTII EMV were 5.86%, 4.88%, and 11.22% at 1st, 3rd, and 6th months, respectively. In Group 2 (PDT+IVB), VA improved in 9, remained unchanged in 8, decreased in 6 eyes. PERG P50 amplitudes were decreased as 10.15%, 5.8%, and 0.1% and HRTII EMV were decreased as 13.07%, 12.17%, and 14.87% at 1st, 3rd, and 6th months, respectively. Conclusion: Verteporfin and PDT are effective and safe methods that preserve VA in subfoveal choroidal neovascular membranes due to neovascular AMD.

show abstract

“…Clinical studies have shown that the intravitreal use of ranibizumab is very effective and reliable in treating age-related macular degeneration [5,8]. The clinical protocol for using the drug is three doses of intravitreal injections that are one month apart [9,10]. The continuation of monthly injections after 3 months is decided according to the patient's clinical, angiographic, and optical coherence tomography (OCT) findings.…”

Section: Introductionmentioning

confidence: 99%

Peptide Nanofiber System for Sustained Delivery of Anti-VEGF Proteins to the Eye Vitreous

et al. 2023

View full text Add to dashboard Cite

Ranibizumab is a recombinant VEGF-A antibody used to treat the wet form of age-related macular degeneration. It is intravitreally administered to ocular compartments, and the treatment requires frequent injections, which may cause complications and patient discomfort. To reduce the number of injections, alternative treatment strategies based on relatively non-invasive ranibizumab delivery are desired for more effective and sustained release in the eye vitreous than the current clinical practice. Here, we present self-assembled hydrogels composed of peptide amphiphile molecules for the sustained release of ranibizumab, enabling local high-dose treatment. Peptide amphiphile molecules self-assemble into biodegradable supramolecular filaments in the presence of electrolytes without the need for a curing agent and enable ease of use due to their injectable nature—a feature provided by shear thinning properties. In this study, the release profile of ranibizumab was evaluated by using different peptide-based hydrogels at varying concentrations for improved treatment of the wet form of age-related macular degeneration. We observed that the slow release of ranibizumab from the hydrogel system follows extended- and sustainable release patterns without any dose dumping. Moreover, the released drug was biologically functional and effective in blocking the angiogenesis of human endothelial cells in a dose-dependent manner. In addition, an in vivo study shows that the drug released from the hydrogel nanofiber system can stay in the rabbit eye’s posterior chamber for longer than a control group that received only a drug injection. The tunable physiochemical characteristics, injectable nature, and biodegradable and biocompatible features of the peptide-based hydrogel nanofiber show that this delivery system has promising potential for intravitreal anti-VEGF drug delivery in clinics to treat the wet form age-related macular degeneration.

show abstract

Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

Cited by 9 publications

References 17 publications

Do published trial results influence physician prescribing patterns? Intravitreal antivascular endothelial growth factor usage by the United States Ophthalmologists before and after Protocol T study

Do published trial results influence physician prescribing patterns? Intravitreal antivascular endothelial growth factor usage by the United States Ophthalmologists before and after Protocol T study

Evaluation of Photodynamic Therapy-Combined Intravitreal Bevacizumab in Age Related Macular Degeneration

Peptide Nanofiber System for Sustained Delivery of Anti-VEGF Proteins to the Eye Vitreous

Contact Info

Product

Resources

About